Erratum to: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122)

Christine M. Fillmore; Chunxiao Xu; Pooja T. Desai; Joanne M. Berry; Samuel P. Rowbotham; Yi Jang Lin; Haikuo Zhang; Victor E. Marquez; Peter S. Hammerman; Kwok Kin Wong; Carla F. Kim

doi:10.1038/s41586-018-0580-6

Erratum to: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122)

Christine M. Fillmore, Chunxiao Xu, Pooja T. Desai, Joanne M. Berry, Samuel P. Rowbotham, Yi Jang Lin, Haikuo Zhang, Victor E. Marquez, Peter S. Hammerman, Kwok Kin Wong, Carla F. Kim

Toxicology and Cancer Biology

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Abstract

We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources¹. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.

Original language	English
Pages (from-to)	E27
Journal	Nature
Volume	563
Issue number	7732
DOIs	https://doi.org/10.1038/s41586-018-0580-6
State	Published - Nov 22 2018

Bibliographical note

Publisher Copyright:
© 2018, Springer Nature Limited.

ASJC Scopus subject areas

General

Access to Document

10.1038/s41586-018-0580-6

Cite this

Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y. J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K. K., & Kim, C. F. (2018). Erratum to: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122). Nature, 563(7732), E27. https://doi.org/10.1038/s41586-018-0580-6

@article{98cc4c20032343cc914b3fb25318e1e0,

title = "Erratum to: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122)",

abstract = "We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources1. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.",

author = "Fillmore, {Christine M.} and Chunxiao Xu and Desai, {Pooja T.} and Berry, {Joanne M.} and Rowbotham, {Samuel P.} and Lin, {Yi Jang} and Haikuo Zhang and Marquez, {Victor E.} and Hammerman, {Peter S.} and Wong, {Kwok Kin} and Kim, {Carla F.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",

year = "2018",

month = nov,

day = "22",

doi = "10.1038/s41586-018-0580-6",

language = "English",

volume = "563",

pages = "E27",

number = "7732",

}

TY - JOUR

T1 - Erratum to

T2 - EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122)

AU - Fillmore, Christine M.

AU - Xu, Chunxiao

AU - Desai, Pooja T.

AU - Berry, Joanne M.

AU - Rowbotham, Samuel P.

AU - Lin, Yi Jang

AU - Zhang, Haikuo

AU - Marquez, Victor E.

AU - Hammerman, Peter S.

AU - Wong, Kwok Kin

AU - Kim, Carla F.

PY - 2018/11/22

Y1 - 2018/11/22

N2 - We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources1. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.

AB - We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources1. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85056938713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056938713&partnerID=8YFLogxK

U2 - 10.1038/s41586-018-0580-6

DO - 10.1038/s41586-018-0580-6

M3 - Comment/debate

C2 - 30250255

AN - SCOPUS:85056938713

VL - 563

SP - E27

IS - 7732

ER -

Erratum to: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors (Nature, (2015), 520, 7546, (239-242), 10.1038/nature14122)

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this